Evogene Receives Formal Nasdaq Delisting Notice for Bid Price Deficiency, Faces September Deadline
EVGN is trading near its 52-week low of $0.72 (9.8% above the low) on light trading volume (0.1× avg).
Summary
Evogene Ltd. received a formal notice from Nasdaq regarding its non-compliance with the minimum bid price rule, initiating a 180-day period to regain compliance and avoid delisting.
Key Events · Corporate Governance and Compliance · EVGN
-
Nasdaq Bid Price Deficiency Notice
Evogene Ltd. received a letter from Nasdaq notifying it of non-compliance with Listing Rule 5550(a)(2), as its ordinary shares have traded below $1.00 for 30 consecutive business days.
-
180-Day Compliance Period Granted
The company has until September 28, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days.
-
Reverse Stock Split Under Consideration
Evogene intends to consider a reverse stock split, among other alternatives, to cure the deficiency and regain compliance with the minimum bid requirement.
-
Follows Prior Delisting and Going Concern Disclosures
This formal notice follows a 20-F filing on March 26, 2026, which disclosed substantial doubt about the company's going concern and mentioned imminent Nasdaq delisting, though this 6-K clarifies a specific compliance period.
Analysis · EVGN · Industrial Applications And Services
Evogene Ltd. has received a formal notification from Nasdaq regarding its non-compliance with the minimum bid price rule, as its shares have traded below $1.00 for 30 consecutive business days. This is a critical development for the micro-cap company, which recently disclosed substantial doubt about its ability to continue as a going concern in its 20-F filing on March 26, 2026. While the company has been granted a 180-day compliance period until September 28, 2026, and is considering a reverse stock split, the formal notice adds significant pressure. Maintaining a Nasdaq listing is crucial for investor confidence and access to capital, especially given the prior F-3 filing indicating a major shareholder's intent to sell shares. Failure to regain compliance could lead to delisting and a move to less liquid over-the-counter markets.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 42.5% of the 522 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVGN was trading at $0.79 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $0.72 to $2.42. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.